Dr. Sunitha Vemulapalli (Nallapaneni ...

Dr. Sunitha Vemulapalli

Claim this profile

Aultman Health Foundation

Studies Breast Cancer
Studies Lung Cancer
25 reported clinical trials
76 drugs studied

About Sunitha Vemulapalli

Education:

  • Earned a Medical Degree (MD), with the specific institution not mentioned.

Experience:

  • Specializes in breast cancer care at Aultman Health Foundation.
  • Boasts over 20 years of experience in breast cancer patient care.
  • Integral part of the multidisciplinary team at Aultman's Breast Care Center, recognized as a "Center of Excellence" by the American College of Radiology and fully accredited by the National Accreditation Program for Breast Centers.

Area of expertise

1Breast Cancer
Sunitha Vemulapalli has run 10 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
Stage II
2Lung Cancer
Sunitha Vemulapalli has run 7 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Affiliated Hospitals

Image of trial facility.
Aultman Health Foundation
Image of trial facility.
Aultman Alliance Community Hospital

Clinical Trials Sunitha Vemulapalli is currently running

Image of trial facility.

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria

More about Sunitha Vemulapalli

Clinical Trial Related6 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 10 Active Clinical Trials
Treatments Sunitha Vemulapalli has experience with
  • Paclitaxel
  • Ipatasertib
  • Binimetinib
  • Fulvestrant
  • Biospecimen Collection
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Sunitha Vemulapalli specialize in?
Is Sunitha Vemulapalli currently recruiting for clinical trials?
Are there any treatments that Sunitha Vemulapalli has studied deeply?
What is the best way to schedule an appointment with Sunitha Vemulapalli?
What is the office address of Sunitha Vemulapalli?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security